AAAAAA

   
Results: 1-7 |
Results: 7
TREATING PATIENTS WITH DOCUMENTED ATHEROSCLEROSIS TO NATIONAL CHOLESTEROL EDUCATION PROGRAM-RECOMMENDED LOW-DENSITY-LIPOPROTEIN CHOLESTEROLGOALS WITH ATORVASTATIN, FLUVASTATIN, LOVASTATIN AND SIMVASTATIN
Authors: BROWN AS BAKKERARKEMA RG YELLEN L HENLEY RW GUTHRIE R CAMPBELL CF KOREN M WOO W MCLAIN R
Citation: As. Brown et al., TREATING PATIENTS WITH DOCUMENTED ATHEROSCLEROSIS TO NATIONAL CHOLESTEROL EDUCATION PROGRAM-RECOMMENDED LOW-DENSITY-LIPOPROTEIN CHOLESTEROLGOALS WITH ATORVASTATIN, FLUVASTATIN, LOVASTATIN AND SIMVASTATIN, Journal of the American College of Cardiology, 32(3), 1998, pp. 665-672
IMPAIRED GLUCOSE-TOLERANCE IS NORMALIZED BY TREATMENT WITH THE THIAZOLIDINEDIONE TROGLITAZONE (VOL 20, PG 188, 1997)
Authors: ANTONUCCI T WHITCOMB R NORRIS RM MCLAIN R LOCKWOOD D
Citation: T. Antonucci et al., IMPAIRED GLUCOSE-TOLERANCE IS NORMALIZED BY TREATMENT WITH THE THIAZOLIDINEDIONE TROGLITAZONE (VOL 20, PG 188, 1997), Diabetes care, 21(4), 1998, pp. 678-678
THE MAB MUSHROOM STUDY AS A TEACHING CASE EXAMPLE OF INTERDISCIPLINARY AND SUSTAINABLE FORESTRY RESEARCH
Authors: MCLAIN R JONES E LIEGEL L
Citation: R. Mclain et al., THE MAB MUSHROOM STUDY AS A TEACHING CASE EXAMPLE OF INTERDISCIPLINARY AND SUSTAINABLE FORESTRY RESEARCH, Ambio, 1998, pp. 34-35
COST-EFFECTIVENESS OF TREATMENT TO NATIONAL CHOLESTEROL EDUCATION PANEL (NCEP) TARGETS WITH HMG-COA REDUCTASE INHIBITORS - TRIAL DESIGN
Authors: BLACK D DAVIDSON M KOREN M BAKKERARKEMA R TRESH P MCLAIN R SMITH D HUNNINGHAKE D
Citation: D. Black et al., COST-EFFECTIVENESS OF TREATMENT TO NATIONAL CHOLESTEROL EDUCATION PANEL (NCEP) TARGETS WITH HMG-COA REDUCTASE INHIBITORS - TRIAL DESIGN, PharmacoEconomics, 12(2), 1997, pp. 278-285
IMPAIRED GLUCOSE-TOLERANCE IS NORMALIZED BY TREATMENT WITH THE THIAZOLIDINEDIONE TROGLITAZONE
Authors: ANTONUCCI T WHITCOMB R MCLAIN R LOCKWOOD D
Citation: T. Antonucci et al., IMPAIRED GLUCOSE-TOLERANCE IS NORMALIZED BY TREATMENT WITH THE THIAZOLIDINEDIONE TROGLITAZONE, Diabetes care, 20(2), 1997, pp. 188-193
A 4-YEAR, PLACEBO-CONTROLLED STUDY OF ATORVASTATIN AS PREVENTION OF CHD END-POINTS IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS
Authors: GMEREK Z MCLAIN R NAWROCKI J
Citation: Z. Gmerek et al., A 4-YEAR, PLACEBO-CONTROLLED STUDY OF ATORVASTATIN AS PREVENTION OF CHD END-POINTS IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS, Diabetes, 46, 1997, pp. 1379-1379
AN INVESTIGATOR-BLINDED, RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED TRIAL OF THE EFFECT OF TROGLITAZONE (CI-991) ON IMPAIRED GLUCOSE-TOLERANCE (IGT) AND INSULIN-RESISTANCE
Authors: ANTONUCCI T NORRIS R MCLAIN R WHITCOMB R
Citation: T. Antonucci et al., AN INVESTIGATOR-BLINDED, RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED TRIAL OF THE EFFECT OF TROGLITAZONE (CI-991) ON IMPAIRED GLUCOSE-TOLERANCE (IGT) AND INSULIN-RESISTANCE, Diabetes, 43, 1994, pp. 10000079-10000079
Risultati: 1-7 |